BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17823551)

  • 1. Molecular studies of vestibular schwannomas: a review.
    Welling DB; Packer MD; Chang LS
    Curr Opin Otolaryngol Head Neck Surg; 2007 Oct; 15(5):341-6. PubMed ID: 17823551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biology of vestibular schwannomas.
    Chang LS; Welling DB
    Methods Mol Biol; 2009; 493():163-77. PubMed ID: 18839347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level.
    Neff BA; Welling DB; Akhmametyeva E; Chang LS
    Otol Neurotol; 2006 Feb; 27(2):197-208. PubMed ID: 16436990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular biology and novel treatments of vestibular schwannomas.
    Fong B; Barkhoudarian G; Pezeshkian P; Parsa AT; Gopen Q; Yang I
    J Neurosurg; 2011 Nov; 115(5):906-14. PubMed ID: 21800959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene discovery using a human vestibular schwannoma cDNA library constructed from a patient with neurofibromatosis type 2 (NF2).
    Halum SL; Erbe CB; Friedland DR; Wackym PA
    Otolaryngol Head Neck Surg; 2003 Mar; 128(3):364-71. PubMed ID: 12646839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].
    Sabol Z; Kipke-Sabol L; Miklić P; Hajnsek-Propadalo S; Sabol F
    Lijec Vjesn; 2006; 128(9-10):309-16. PubMed ID: 17128670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the "two-hit hypothesis" in NF2: tests of two-hit and three-hit models of vestibular schwannoma development.
    Woods R; Friedman JM; Evans DG; Baser ME; Joe H
    Genet Epidemiol; 2003 May; 24(4):265-72. PubMed ID: 12687643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF2: the wizardry of merlin.
    Xiao GH; Chernoff J; Testa JR
    Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoblotting analysis of schwannomin/merlin in human schwannomas.
    Harwalkar JA; Lee JH; Hughes G; Kinney SE; Golubić M
    Am J Otol; 1998 Sep; 19(5):654-9. PubMed ID: 9752976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genesis and biology of vestibular schwannomas.
    Roche PH; Bouvier C; Chinot O; Figarella-Branger D
    Prog Neurol Surg; 2008; 21():24-31. PubMed ID: 18810196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathogenesis and molecular pathology of vestibular schwannoma].
    Brodhun M; Stahn V; Harder A
    HNO; 2017 May; 65(5):362-372. PubMed ID: 27421984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updates on Tumor Biology in Vestibular Schwannoma.
    Nourbakhsh A; Dinh CT
    Otolaryngol Clin North Am; 2023 Jun; 56(3):421-434. PubMed ID: 37121611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function.
    Surace EI; Haipek CA; Gutmann DH
    Oncogene; 2004 Jan; 23(2):580-7. PubMed ID: 14724586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma.
    Jacob A; Lee TX; Neff BA; Miller S; Welling B; Chang LS
    Otol Neurotol; 2008 Jan; 29(1):58-68. PubMed ID: 18199958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tumour suppressor protein NF2/merlin: the puzzle continues.
    Hovens CM; Kaye AH
    J Clin Neurosci; 2001 Jan; 8(1):4-7. PubMed ID: 11148074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biology of familial and sporadic vestibular schwannomas: implications for novel therapeutics.
    Sughrue ME; Yeung AH; Rutkowski MJ; Cheung SW; Parsa AT
    J Neurosurg; 2011 Feb; 114(2):359-66. PubMed ID: 19943731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAP, a protein interacting with a tumor suppressor, merlin, through the run domain.
    Lee IK; Kim KS; Kim H; Lee JY; Ryu CH; Chun HJ; Lee KU; Lim Y; Kim YH; Huh PW; Lee KH; Han SI; Jun TY; Rha HK
    Biochem Biophys Res Commun; 2004 Dec; 325(3):774-83. PubMed ID: 15541357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of p21 (waf1) in merlin deficient sporadic vestibular schwannomas.
    Wu H; Chen Y; Wang ZY; Li W; Li JQ; Zhang L; Lu YJ
    Neuroscience; 2010 Sep; 170(1):149-55. PubMed ID: 20600642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.
    Blakeley J
    Curr Opin Otolaryngol Head Neck Surg; 2012 Oct; 20(5):372-9. PubMed ID: 22931905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
    Cumpston EC; Rhodes SD; Yates CW
    Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.